Related Experiment Video
Updated: Dec 18, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
TFII-I-mediated polymerase pausing antagonizes GLI2 induction by TGFβ
Angela L McCleary-Wheeler1,2, Brooke D Paradise1,2, Luciana L Almada1
1Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
The modulation of GLI2, an oncogenic transcription factor commonly upregulated in cancer, is in many cases not due to genetic defects, suggesting dysregulation through alternative mechanisms. The identity of these molecular events remains for the most part unknown. Here, we identified TFII-I as a novel repressor of GLI2 expression. Mapping experiments suggest that the INR region of the GLI2 promoter is necessary for GLI2 repression. ChIP studies showed that TFII-I binds to this INR. TFII-I knockdown decreased the binding of NELF-A, a component of the promoter-proximal pausing complex at this site, and enriched phosphorylated RNAPII serine 2 in the GLI2 gene body. Immunoprecipitation studies demonstrate TFII-I interaction with SPT5, another pausing complex component. TFII-I overexpression antagonized GLI2 induction by TGFβ, a known activator of GLI2 in cancer cells. TGFβ reduced endogenous TFII-I binding to the INR and increased RNAPII SerP2 in the gene body. We demonstrate that this regulatory mechanism is not exclusive of GLI2. TGFβ-induced genes CCR7, TGFβ1 and EGR3 showed similar decreased TFII-I and NELF-A INR binding and increased RNAPII SerP2 in the gene body post-TGFβ treatment. Together these results identify TFII-I as a novel repressor of a subset of TGFβ-responsive genes through the regulation of RNAPII pausing.
Insights
Transcription factor TFII-I represses GLI2 expression by regulating RNA polymerase II pausing. This mechanism impacts cancer-related genes and is influenced by TGFβ signaling.
Area of Science:
- Molecular Biology
- Gene Regulation
- Cancer Biology
Background:
- GLI2, an oncogenic transcription factor, is often upregulated in cancer through non-genetic mechanisms.
- The specific molecular events driving GLI2 dysregulation are largely unknown.
Purpose of the Study:
- To identify novel regulators of GLI2 expression.
- To elucidate the mechanism by which TFII-I modulates GLI2.
Main Methods:
- Chromatin immunoprecipitation (ChIP) assays to assess protein binding to the GLI2 promoter.
- RNA polymerase II (RNAPII) phosphorylation analysis.
- Immunoprecipitation studies to identify protein interactions.
- Gene expression analysis in response to TFII-I modulation and TGFβ treatment.
Main Results:
- TFII-I was identified as a novel repressor of GLI2 expression, binding to the GLI2 promoter's INR region.
- TFII-I regulates RNAPII pausing at the GLI2 gene, influencing transcription.
- TFII-I overexpression antagonizes TGFβ-induced GLI2 activation.
- This mechanism extends to other TGFβ-responsive genes.
Conclusions:
- TFII-I acts as a repressor of GLI2 and other TGFβ-responsive genes.
- Regulation occurs via modulation of RNAPII pausing at the promoter.
- Identifies a novel pathway for controlling oncogenic transcription factor expression in cancer.
Related Concept Videos
TGF - β Signaling Pathway
Transcription Elongation Factors
The transcription elongation is regulated via pausing of RNA polymerase on several occasions during transcription. In bacteria, these halts are necessary because the transcription of DNA into mRNA is coupled to the translation of that mRNA...
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
General Transcription Factors
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Activation and Inactivation of G Proteins

